Literature DB >> 24797186

Prevalence and correlates of willingness to participate in a rectal microbicide trial among men who have sex with men in Bangkok.

Warunee Thienkrua1, Catherine S Todd, Supaporn Chaikummao, Wichuda Sukwicha, Somsak Yafant, Narongritt Tippanont, Anchalee Varangrat, Pechpailin Khlaimanee, Timothy H Holtz.   

Abstract

Rectal microbicides (RMs) hold promise as a HIV prevention method to reduce transmission among men who have sex with men (MSM). To assess RM trial feasibility in Bangkok, we measured prevalence and correlates of willingness to participate among Thai MSM observational cohort participants. Between April 2006 and December 2010, 1744 MSM enrolled in the Bangkok MSM Cohort Study; at 12 months, RM trial participation willingness was measured. We evaluated correlates of RM trial participation willingness using logistic regression analysis. Participants completing the 12-month visit (81.4%, n = 1419) had a mean age of 27.3 years (SD = 6.1), and 65.5% and 86.1% reported having a steady partner or anal intercourse (AI) in the past four months, respectively. Most (79.1%, n = 1123) participants reported willingness to participate in an RM trial, which, in multivariable analysis, was independently associated with insertive only (adjusted odds ratio [AOR] = 3.25, 95% CI: 1.82-5.81) or receptive/versatile role AI (AOR = 3.07, 95% CI: 1.88-5.01), and being paid for sex (AOR = 12.15, 95% CI: 1.67-88.21) in the past four months, and believing that people with AIDS look sick (AOR = 1.92, 95% CI: 1.23-2.98). Of hypothetical RM trial features to increase enrollment likelihood, the most (91.1%) compelling was that the study be approved by the Thai ethics committee, followed by the study site offering evening hours (88.9%). Reasons not to participate were not wanting a rectal examination (29.5%) or fluid collected from the penis or anus (24.6%) and not wanting the placebo (23.0%). RM trial participation willingness was high, particularly for those with greater HIV acquisition risk, within this Thai MSM cohort, suggesting feasibility of an RM trial. Addressing potential barriers to trial entry may be useful in educational materials to optimize recruitment.

Entities:  

Keywords:  HIV; clinical trial; men who have sex with men; prevention; rectal microbicide

Mesh:

Substances:

Year:  2014        PMID: 24797186     DOI: 10.1080/09540121.2014.913763

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  5 in total

1.  Anal Douche Practices and Willingness to Use a Rectal Microbicide Enema for HIV Prevention and Associated Factors Among an Internet Sample of HIV-Negative and HIV-Discordant Male Couples in the US.

Authors:  Jason W Mitchell; Amber I Sophus; Ji-Young Lee; Andrew E Petroll
Journal:  AIDS Behav       Date:  2016-11

2.  PrEP Implementation Science: State-of-the-Art and Research Agenda.

Authors:  Carlos F Cáceres; Kenneth H Mayer; Rachel Baggaley; Kevin R O'Reilly
Journal:  J Int AIDS Soc       Date:  2015-07-20       Impact factor: 5.396

3.  HIV pre-exposure prophylaxis and health and community systems in the Global South: Thailand case study.

Authors:  Donn Colby; Kriengkrai Srithanaviboonchai; Suphak Vanichseni; Sumet Ongwandee; Nittaya Phanuphak; Michael Martin; Kachit Choopanya; Suwat Chariyalertsak; Frits van Griensven
Journal:  J Int AIDS Soc       Date:  2015-07-20       Impact factor: 5.396

4.  The willingness to participate in biomedical research involving human beings in low- and middle-income countries: a systematic review.

Authors:  Joyce L Browne; Connie O Rees; Johannes J M van Delden; Irene Agyepong; Diederick E Grobbee; Ama Edwin; Kerstin Klipstein-Grobusch; Rieke van der Graaf
Journal:  Trop Med Int Health       Date:  2019-01-08       Impact factor: 2.622

5.  Understanding women's motivations to participate in MTN-003/VOICE, a phase 2b HIV prevention trial with low adherence.

Authors:  Ariana W K Katz; Barbara S Mensch; Kubashni Woeber; Petina Musara; Juliane Etima; Ariane van der Straten
Journal:  BMC Womens Health       Date:  2019-01-25       Impact factor: 2.809

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.